Evaluation of Cannabis and Cannabinoid Product Use, Knowledge, and Attitudes in the Eczema Community

Background: Data to date supports the potential for targeting the cutaneous endocannabinoid system to treat eczematous dermatoses. However, our understanding of patient knowledge and utilization of cannabis/cannabis-derived products as treatments for eczema is limited, highlighting both a gap and opportunity to engage with the eczema community.

Methods: An online survey assessing the use, knowledge, and attitudes of a broad scope of cannabis product types was advertised by the National Eczema Association (NEA) via social media and NEA network dissemination.

Results: Of 76 respondents to the survey, 69 (90.79%) were individuals diagnosed with eczema, 7 (9.21%) were primary caregivers of a dependent diagnosed with eczema. Respondents most frequently used OTC products purchased without recommendation from a dermatologist (22 [36.07%], n=61) and least frequently used medical cannabis recommended by a dermatologist (2 [3.12%], n=64). All respondents supported medical cannabis use (50 [100%], n=50) and most respondents (47 [94%], n=50) would be comfortable seeing a dermatologist who recommended medical cannabis. 94% of respondents (47, n=50) would be interested in learning about using medical cannabis for treatment of eczema, but most had never discussed this topic with their healthcare provider (54 [93.10%], n=58). 46.67% of respondents (28, n=60) were unsure if OTC cannabis-derived products were regulated by the FDA.

Conclusion: Eczema patients are open to learning about cannabinoids and many are already using OTC products. As both consumer interest/use and the cannabis industry continue to outpace medical research and guidelines, dermatologists need to be prepared to counsel patients on cannabinoid applications in dermatology. J Drugs Dermatol. 2022;21(4):413-419. doi:10.36849/JDD.6615.